Evaluation of the stability of aciclovir in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy.


Journal

European journal of hospital pharmacy : science and practice
ISSN: 2047-9956
Titre abrégé: Eur J Hosp Pharm
Pays: England
ID NLM: 101578294

Informations de publication

Date de publication:
06 Dec 2023
Historique:
received: 29 03 2023
accepted: 07 11 2023
medline: 10 12 2023
pubmed: 10 12 2023
entrez: 10 12 2023
Statut: aheadofprint

Résumé

To investigate the stability of aciclovir solutions in elastomeric devices used for outpatient parenteral antimicrobial therapy (OPAT). Triplicates of two elastomeric devices, Accufuser and Easypump II, were filled with a solution of 200 mg, 2400 mg, and 4500 mg aciclovir in 240 mL 0.9% w/v saline. Devices were stored at room temperature for 14 days, followed by 24 hours storage at 32°C. Assessment using a stability indicating assay, pH and subvisible particle analysis was undertaken at 11 time points throughout the study. Aciclovir solution at 200 mg and 2400 mg in 240 mL was stable for 14 days at room temperature (<20°C) and 24 hours of 32°C 'in-use' temperature exposure, remaining above the 95% limit for NHS stability protocols. The high dose was also stable for 14 days at room temperature, but when stored at 32°C there was precipitation of aciclovir within 4 hours in both devices. The precipitate was confirmed as aciclovir and precipitation was not a sign of chemical degradation. Aciclovir concentrations above 2400 mg/240 mL are liable to precipitation and cannot be recommended for OPAT services because of heightened risks of nephrotoxicity. Aciclovir solution can be given as a continuous 24-hour infusion for OPAT services at a concentration range of 200-2400 mg in 240 mL in Accufuser and Easypump II elastomeric devices following 14 days storage at room temperature, protected from light.

Identifiants

pubmed: 38071555
pii: ejhpharm-2023-003784
doi: 10.1136/ejhpharm-2023-003784
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Fekade Bruck Sime (FB)

University of Queensland Centre for Clinical Research, Brisbane, Queensland, Australia f.sime@uq.edu.au.

Steven Wallis (S)

University of Queensland Centre for Clinical Research, Brisbane, Queensland, Australia.

Conor Jamieson (C)

NHS England, Birmingham, UK.

Tim Hills (T)

Pharmacy Department, Nottingham University Hospitals, Nottingham, UK.

Mark Gilchrist (M)

Department of Pharmacy/Infection, Imperial College Healthcare NHS Trust, London, UK.

Mark Santillo (M)

University Hospitals Plymouth NHS Trust, Plymouth, UK.
University Hospitals Bristol and Weston NHS Trust, Bristol, UK.

R Andrew Seaton (RA)

Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, UK.

Felicity Drummond (F)

British Society for Antimicrobial Chemotherapy, Birmingham, UK.

Jason Roberts (J)

University of Queensland Centre for Clinical Research, Brisbane, Queensland, Australia.
Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, Queensland, Australia.
Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier, Nîmes, France.

Classifications MeSH